In brief: Select Vaccines, Life Therapeutics, Chemeq

Select Vaccines' (ASX:SLT) executive chairman Jeremy Cooper has retired as a director and will be replaced by Robin Beaumont as non-executive chairman. Dr Martin Soust has become the Select Vaccines' full-time managing director, relinquishing his role as part-time CEO at Premier Bionics (ASX:PBI) but remaining with the company as a non-executive director. Peter Marks has been appointed as a non-executive director for Select Vaccines.

One of the two founders of Life Therapeutics (ASX:LFE), Perry Manusu, will step down as a director at the company's AGM later this year but will remain as a member of the scientific advisory board. Prakash Patel has been appointed company secretary following Rachel Freeman's move to the US in January to head up Human Resources and her recent appointment as chief operating officer Atlanta. Following the company's decision to list on the NASDAQ and a legal requirement to have a US based CFO, John Manusu has chosen to remain in Australia for family reasons and will step aside as CFO on December 31.

Chemeq (ASX:CMQ) has been granted patent protection for the use of CHEMYDE polymeric antimicrobial in Japan to the year 2019.